Phosphodiesterase type III (PDE III) inhibitors or Ca2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy

Details for Australian Patent Application No. 2009319076 (hide)

Owner Boehringer Ingelheim Vetmedica GmbH

Inventors Daemmgen, Juergen

Agent Spruson & Ferguson

Pub. Number AU-A-2009319076

PCT Pub. Number WO2010/060874

Priority 08169897.9 25.11.08 EP

Filing date 23 November 2009

Wipo publication date 3 June 2010

International Classifications

A61K 31/10 (2006.01)

A61K 31/277 (2006.01)

A61K 31/4166 (2006.01)

A61K 31/4178 (2006.01)

A61K 31/4412 (2006.01) - having oxo groups directly attached to the heterocyclic ring

A61K 31/444 (2006.01)

A61K 31/501 (2006.01) - not condensed and containing further heterocyclic rings

A61K 31/635 (2006.01)

A61P 9/04 (2006.01) Drugs for disorders of the cardiovascular system

Event Publications

26 May 2011 PCT application entered the National Phase

  PCT publication WO2010/060874 Priority application(s): WO2010/060874

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009319079-Compounds with guanidine structure and uses thereof as organopolysiloxane polycondensation catalysts

2009319068-A foundation and a method for forming a foundation for a wind turbine tower